The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with infl ammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed.
INTRODUCTION
Anti-tumor necrosis factor-α (anti-TNF) drugs are eff ective in inducing and maintaining remission in patients with infl ammatory bowel diseases (IBD), namely, Crohn's disease (CD) and ulcerative colitis (UC) ( 1 ) . Th is eff ectiveness is associated with mucosal healing, improved quality of life, fewer hospitalizations, and reduced need for surgical procedures (1) (2) (3) (4) .
Discontinuation of anti-TNF treatment can be considered once remission has been achieved. Th e decision to discontinue anti-TNF drugs in patients in remission depends on several factors, such as the cost of the medications, the potential but serious adverse eff ects, and the outcome following elective withdrawal ( 5 ) . Once it has been decided that the drug is to be withdrawn, the optimal time for doing so must be established ( 6 ) .
Studies evaluating this strategy are mostly single-cohort designs, and most of them include a small number of patients and have a short follow-up period ( 7 ) . Th erefore, the risk of relapse aft er withdrawal of anti-TNF medication and the variables that aff ect clinical course aft er withdrawal are not well known. Data from small observational studies of patients who discontinued anti-TNF therapy aft er having achieved clinical remission show that the range of relapse rates is wide (8) (9) (10) (11) (12) (13) (14) .
Th e retreatment with the same anti-TNF drug in patients who relapse aft er the initial withdrawal have been reported to be apparently successful and safe ( 12, (15) (16) (17) , and these factors are essential before deciding whether to discontinue anti-TNF therapy. However, there are many concerns relating to discontinuation of anti-TNF therapy in IBD patients that include not only the risk of relapse, but also the possible loss of effi cacy when the drug is restarted, the risk of infusion reactions and other adverse events at retreatment, and, fi nally, the possibility of losing therapeutic options. Th erefore, currently available data are insuffi cient to make recommendations on when, if ever, anti-TNF therapy can be stopped in patients with IBD.
Th e aims of the present study were to assess the risk of relapse aft er discontinuation of anti-TNF therapy, to identify the factors associated with relapse, to know the rate of response to retreatment with the same anti-TNF drug aft er relapsing, and to evaluate the safety of retreatment with these drugs.
METHODS

Study population
Th e present study was a multicenter, observational, retrospective study conducted at 78 Spanish centers. Th e study population comprised patients diagnosed with CD or UC who had been treated with anti-TNF agents (infl iximab (IFX) or adalimumab (ADA)) to induce remission and in whom these drugs had been discontinued aft er clinical remission was achieved. Th e reasons for discontinuation of anti-TNF treatment were as follows: elective decision (by the physician and/or by the patient), onset of adverse events, and early introduction of thiopurines combined with an anti-TNF agent in order to induce clinical remission of IBD in patients who were naive to immunosuppressive therapy INFLAMMATORY BOWEL DISEASE VOLUME 112 | JANUARY 2017 (top-down strategy). Th e minimum requirement for all patients was to have had received induction treatment with anti-TNF drugs. Th e patients were followed for a minimum of 6 months aft er stopping treatment. Patients who had been treated with anti-TNF drugs for reasons other than IBD or with < 6 months of follow-up aft er discontinuation were excluded. If the patients had more than one attempt to stop the anti-TNF treatment, only the fi rst attempt to discontinue this drug was included in analysis.
Ethical aspects . Th e study was approved by the respective institutional ethics review boards, and was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines.
Data collection
All clinical, endoscopic, and radiological data were obtained from medical records. Th e data collected included demographic data, duration of IBD, smoking habits, previous surgery for IBD, and previous IBD treatments (e.g., immunosuppressants). Clinical, endoscopic, laboratory, and radiological data were collected at three diff erent times during follow-up: at discontinuation of the anti-TNF drug, when the patient relapsed (if this occurred), and at the last follow-up visit. It was considered that the patient had an endoscopy or a magnetic resonance imaging at the moment of withdrawal if these procedures were performed within 30 days before anti-TNF discontinuation. Information about the response to treatment aft er reintroduction of anti-TNF therapy in relapsing patients and occurrence of adverse events aft er reintroduction were also recorded.
Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at Asociación Española de Gastroenterología (AEG; www.aegastro.es ) ( 18 ) . AEG is a nonprofi t Scientifi c and Medical Society focused on Gastroenterology, and it provided this service free of charge, with the sole aim of promoting independent investigator-driven research. REDCap is a secure, web-based application designed to support data capture for research studies, providing (i) an intuitive interface for validated data entry; (ii) audit trails for tracking data manipulation and export procedures; (iii) automated export procedures for seamless data downloads to common statistical packages; and (iv) procedures for importing data from external sources.
Defi nitions
Clinical remission . For luminal CD, remission was defi ned as a Harvey-Bradshaw index score of ≤4 points ( 19 ) . For UC, remission was defi ned as a partial Mayo score of ≤2 points ( 20 ) . In the case of perianal disease, remission was defi ned as the absence of fi stula drainage despite gentle fi nger compression (Fistula Drainage Assessment score) ( 21 ) . Given the retrospective nature of the study, Harvey-Bradshaw index and partial Mayo score were estimated aft er reviewing the medical records.
Endoscopic infl ammation .
In the case of luminal CD, endoscopic activity was classifi ed as mild, moderate, severe, or mucosal healing, as judged by the investigators based on the fi ndings in the endoscopy report.
Given the retrospective design of the study, it was not feasible to calculate endoscopic scores based on the endoscopy records. Th e Rutgeerts index was used to categorize the severity of postsurgical recurrence ( 22 ) . Endoscopic infl ammation in UC patients was classifi ed using the endoscopic subscore of the Mayo index that was applied retrospectively to individual patient reports ( 23 ) .
Radiological remission . For perianal CD, the disease was considered to be in remission if pelvic magnetic resonance imaging demonstrated that the perianal fi stulas tracts showed no signs of activity and were without local complications. In the case of luminal CD patients, the disease was considered to be inactive if the abdominal magnetic resonance imaging did not show contrast enhancement of the wall, edema, or ulcers.
Relapse . As this is a retrospective study, relapse was defi ned as the onset of documented clinical, biochemical, endoscopic, or radiological activity leading to a therapeutic intervention, namely, escalation or modifi cation of medical therapy or surgery for disease control.
Response to retreatment . In patients with luminal CD, remission was defi ned as a Harvey-Bradshaw index of ≤4 points: a partial response was defi ned as a decrease of ≥3 points from baseline. In fi stulizing CD, remission was defi ned as cessation of spontaneous fi stula drainage and lack of drainage aft er gentle fi nger compression, whereas a decrease from baseline in the number of open draining fi stulae of ≥50% or a reduction in fi stula drainage were considered partial response. In UC patients, remission was defi ned as a partial Mayo score of ≤2 points, whereas a decrease of ≥3 points from baseline was considered a partial response. Response to retreatment with anti-TNF therapy was evaluated at 2 time points: 14 weeks (initial response) and the end of follow-up (fi nal response).
Statistical analysis
Th e descriptive analysis of quantitative variables included the mean and s.d. or the median and interquartile range, depending on whether the variables were normally distributed or not. For the categorical variables, the percentage and the 95% confi dence intervals (95% CIs) were provided. Comparisons between means were performed using the t-test for independent samples. Categorical variables were compared using the χ 2 test and the Fisher's exact test or the Wilcoxon rank-sum test according to the distribution of data. Statistical signifi cance was set at P <0.05.
Long-term maintenance of remission was estimated using Kaplan-Meier curves. Survival curves assessing the impact of several variables on long-term remission were compared using the log-rank test. A Cox regression model was constructed to identify predictive factors for relapse. All the variables that reached statistical signifi cance in the univariate analysis and those that were considered clinically relevant were included in the multivariate analysis. Th e dependent variable was the risk of relapse aft er discontinuation of anti-TNF therapy. Th e independent variables were: type of IBD (CD and UC), gender, age at discontinuation
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(included as a continuous variable), surgery because of IBD, current smoking habit, type of anti-TNF drug received (IFX or ADA), duration of anti-TNF treatment, reasons for anti-TNF discontinuation (elective discontinuation, discontinuation because of adverse events, and discontinuation as a part of a top-down strategy), and treatment with immunomodulators (IMMs) aft er discontinuation of anti-TNF therapy.
Th e results were expressed as hazard ratios (HRs) with their corresponding 95% CIs.
RESULTS
Study population
Th e study population comprised 1,055 patients who discontinued anti-TNF drugs aft er achieving clinical remission and met the inclusion criteria. Th e median follow-up time aft er discontinuation was 19 (6-176) months. Th e main characteristics of the patients are summarized in Table 1 . Most patients (74%) had received IFX. Th e reasons for discontinuation were elective decision (75%), adverse events (18%), and remission aft er undergoing a top-down strategy (7%). Th e disease duration in patients undergoing a top-down strategy was shorter than in both elective discontinuation and adverse event groups (9.8, 11.9, and 13.1 months, respectively, P <0.0001). Th e median duration of anti-TNF therapy in the top-down group was shorter than in the other two groups (4, 21, and 14 months, respectively, P <0.0001).
Seventy-two patients treated with IFX received only induction therapy (elective discontinuation group: 30/719 (4%) patients; adverse events group: 12/174 (7%) patients; and top-down group: 30/68 (44%) patients). All the patients treated with ADA received induction and maintenance therapy. Endoscopy fi ndings at discontinuation were available in 474 patients (45%); of these, endoscopy fi ndings were normal (i.e., no activity was detected) in 419 (88%). In the remaining 55 patients (12%), endoscopic activity was mild in 38 (69%). Aft er discontinuation of anti-TNF drugs, 68% of patients received therapy with IMMs (thiopurines or methotrexate).
A total of 460 patients had a normal endoscopy or a normal magnetic resonance imaging at the moment of anti-TNF withdrawal. Th e main characteristics of this subgroup of patients are summarized in Table 2 .
Evolution after discontinuation of anti-TNF therapy
Th e incidence of relapse was 18% per patient-year (95% CI= [17] [18] [19] [20] . Th e median time to relapse aft er discontinuation was 11 (1-140) months, and the cumulative incidence of relapse was 44% (95% CI=41-46): 15% at 6 months, 24% at 1 year, 38% at 2 years, 46% at 3 years, and 56% at 5 years aft er discontinuation. Th e cumulative incidence of relapse during follow-up is shown in Figure 1a .
Evolution by type of IBD . In CD patients, the incidence of relapse was 19% per patient-year (95% CI=17-21), whereas in UC patients the relapse rate was 17% per patient-year (95% CI=15-20). Type of IBD was not associated with the risk of relapse ( P =0.1). Th e cumulative incidence of relapse by type of IBD is shown in Figure 1b and c .
Th e incidence rate of relapse was 17% per patient-year (95% CI=15-18) when the analysis considered only patients receiving IMMs aft er discontinuation, and 26% per patient-year (95% CI=22-30) when the analysis considered only patients who did not continue the treatment with IMMs. Among patients who maintained IMMs aft er discontinuation, the cumulative incidence of relapse was 21% at 1 year, 35% at 2 years, 43% at 3 years, and 53% at 5 years. From the 32% of patients who did not receive IMMs aft er withdrawal, 195 had CD. Of these, 110 (56%) patients relapsed. Th e incidence rate of relapse in this group of patients was 28% per patient-year (95% CI=24-33). On the other hand, the incidence rate of relapse in CD patients who were under IMMs aft er withdrawal was 17% per patient-year (95% CI=15-19). Patients who relapsed within 3 months of stopping the anti-TNF therapy (early relapse) were more oft en female (64% vs. 51%, P =0.03), and had received less frequently treatment with IMMs aft er the withdrawal of the anti-TNF (56% vs. 68%, P =0.04).
Evolution in patients in deep remission . In patients in deep remission, the incidence rate of relapse was 19% per patient-year (95% CI=17-22): 19% per patient-year in CD (95% CI=16-22), and 19% per patient-year in UC (95% CI=15-24). Th e relapse rate aft er 1 year of discontinuation was 22% in CD patients and 20% in UC patients.
Predictors of relapse after discontinuation of anti-TNF therapy
Th e univariate analysis showed that gender, treatment with IMMs aft er discontinuation of anti-TNF therapy, type of anti-TNF drug received, and reasons for discontinuation (elective discontinuation, discontinuation because of adverse events, and discontinuation as part of a top-down strategy) were the only variables associated with the risk of relapse aft er discontinuation ( Figures 2  and 3 ). No statistical diff erences were observed in the risk of relapse aft er discontinuation between patients who maintained thiopurines and patients who continued methotrexate (41% vs. 45%; P >0.05).
In the multivariate analysis ( Table 3 ) , the variables associated with a higher risk of relapse were treatment with ADA vs. IFX (HR=1.29; 95% CI=1.03-1.6), elective discontinuation (vs. discontinuation as part of a top-down strategy; HR=1.82; 95% CI=1.19-2.79), and discontinuation because of adverse events (vs. the discontinuation as part of a top-down strategy; HR=1.95; 95% CI=1. 22-3.12) . Treatment with IMMs (vs. no treatment) aft er discontinuation and older age at discontinuation (HR=0.99; 95% CI=0.98-0.99) were associated with a lower risk of relapse (HR=0.7; 95% CI=0.57-0.88). Gender, type of IBD, current smoking habit, prior surgery related to IBD, duration of anti-TNF treatment, and previous treatment with an anti-TNF drug had no impact on the risk of relapse.
Predictors of relapse by type of IBD .
A subanalysis was performed in patients with UC and CD. In UC, none of the factors were statistically signifi cant. In CD, disease localization (colonic INFLAMMATORY BOWEL DISEASE VOLUME 112 | JANUARY 2017
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vs. ileal) and disease behavior (stricturing vs. infl ammatory) were associated with the risk of relapse. Moreover, the variables that were signifi cant in the general multivariate analysis were also signifi cant in this subanalysis ( Table 4 ) , adjusted by the duration of anti-TNF treatment.
A sensitivity analysis was performed with the patients who maintained IMMs aft er discontinuation of anti-TNF. Older age at discontinuation was independently associated with a lower risk of relapse (HR=0.98; 95% CI=0.97-9.98). On the other hand, elective discontinuation (vs. discontinuation as part of a top-down strategy; Casanova et al.
that excluded those with CD in which perianal disease was the indication for anti-TNF therapy, the only factor associated with a higher risk of relapse was older age at discontinuation (HR=0.98; 95% CI=0.97-0.99). Th us, the presence of mucosal lesions in the endoscopy was not associated with a higher risk of relapse aft er discontinuation.
Predictors of relapse in patients in deep remission . In the univariate analysis performed in the group of CD patients with clinical remission and mucosal healing, the reasons for discontinuation (elective discontinuation, discontinuation because of adverse events, and discontinuation as part of a top-down strategy) was the only variable associated with the risk of relapse aft er withdrawal ( P <0.0001). In UC patients, disease extension (proctitis, left -side colitis, and extensive colitis) was the only HR=1.6; 95% CI=1.06-2.51) and discontinuation because of adverse events (vs. the discontinuation as part of a top-down strategy; HR=1.9; 95% CI=1.14-3.23) were signifi cantly associated with a higher risk of relapse. Th e model was also evaluated considering only CD patients who had received the anti-TNF agent owing to luminal disease (in comparison with UC), and the type of IBD was not associated with a higher risk of relapse (HR=1.03; 95% CI=0.79-1.34). Furthermore, we repeated the analysis aft er excluding patients with luminal CD to know whether the risk of relapse was higher among patients who received the anti-TNF drug owing to perianal CD in comparison with UC and observed that the risk was not increased (HR=1.04; 95% CI=0.77-1.41).
In a subanalysis that included the 444 IBD patients who had undergone endoscopic evaluation before discontinuation, and 
variable statistically signifi cant ( P =0.002).
In the multivariate analysis, the only variable associated with a higher risk of relapse in CD patients was the discontinuation of anti-TNF treatment because of adverse events (vs. the discontinuation as part of a top-down strategy; HR=5.26; 95% CI=1.94-14.27), whereas older age at anti-TNF discontinuation was associated with a lower risk of relapse (HR=0.97; 95% CI=0.96-0.99). Gender, type of IBD, current smoking habit, prior surgery related to IBD, duration of anti-TNF treatment of >2 years, treatment with IMMs aft er anti-TNF discontinuation, and elective discontinuation (vs. discontinuation as a part of top-down strategy) were not associated with the risk of relapse. In UC patients, none of these variables were associated with the risk of relapse.
Retreatment with anti-TNF drugs after relapse
Of the 467 (44%) patients who relapsed, 310 (69%) were retreated with the same anti-TNF drug, 128 (28%) received another drug, and 14 (3%) were operated on (12 patients had CD and 2 patients 
Retreatment with anti-TNF drugs aft er relapse by type of IBD .
Of the 338 CD patients who relapsed, 250 (74%) were retreated with the same anti-TNF, 74 (22%) were treated with another drug, and 14 (4%) were operated on. In the case of UC patients, of the 129 patients who relapsed, 70 (54%) were retreated with the same anti-TNF, 57 (44%) received another drug, and 2 (2%) were operated on. Response to retreatment by type of IBD is shown in Figure 4b .
Retreatment with anti-TNF drugs aft er relapse in patients in deep remission . Of the 460 patients in deep remission who discontinued the anti-TNF, 177 relapsed. Of these, 125 (71%) were retreated with the same anti-TNF, 49 (28%) received another drug, and 3 (1%) had surgery. At the end of follow-up, 78% (95% CI=70-85) of the patients were in clinical remission and 15% (95% CI=8-20) had a partial response.
Safety of the retreatment after relapse
Aft er retreatment, 34 of the total of patients who received an anti-TNF drug (11%) experienced adverse events. Of these, 16 had infusion reactions, leading to the interruption of treatment in 6 cases. Nine patients presented adverse skin reactions but none of them had to discontinue treatment. Of the 6 patients who developed infections (2 pharyngitis, 1 varicella, 1 intraabdominal abscess, 1 candidal intertrigo, and 1 miliary tuberculosis), 2 had to discontinue treatment because of the infection (1 of the patients with pharyngitis and the patient with miliary tuberculosis). Finally, 3 patients experienced other types of adverse events (dilated cardiomyopathy, memory loss, and leukopenia, respectively) and had to discontinue therapy.
DISCUSSION
To our knowledge, the cohort analyzed in this study is the largest to date in IBD (1,055 patients, median follow-up of 2.4 years) in which the strategy of discontinuing anti-TNF therapy aft er clinical remission has been evaluated. We found that the incidence of relapse was 18% per patient-year and that the cumulative incidence of relapse was 44% per patient-year. Th ese fi ndings confi rm the relatively short duration of remission aft er discontinuation of anti-TNF therapy. Other studies have reported similar relapse rates ( 10, 16, (24) (25) (26) (27) . Th e relapse rate at 1 year aft er discontinuation was 24%, which was slightly lower than in other series ( 10, 16, 28 ) , probably because almost all patients in whom endoscopic or radiologic activity had been investigated before stopping anti-TNF drugs had inactive disease. In fact, the relapse rate within 1 year of discontinuation in this group of patients was 14%. Moreover, endoscopic activity was mild in most of the patients in whom activity was detected (12%). Consequently, nearly 50% of the patients in our study stopped anti-TNF therapy aft er having achieved stable remission. Experience with follow-up periods of >1 year aft er stopping anti-TNFs is very limited. A very recent meta-analysis of 27 studies reported an overall risk of relapse of 44% in IBD patients who discontinued anti-TNF agents aft er achieving clinical remishad UC). Of the 310 retreated patients, 78% received anti-TNF induction therapy. In addition, 67% (95% CI=61-72%) of these patients achieved clinical remission aft er 14 weeks of treatment. At the end of follow-up, 75% of patients (95% CI=70-80) were in clinical remission and 13% (95% CI=9-18) had a partial response ( Figure 4a ). Clinical remission was also achieved at the end of follow-up by 79% of patients (95% CI=72-85) retreated with IFX and 69% of the patients retreated with ADA (95% CI=60-77).
Out of the 310 patients, 38 (28%) restarted anti-TNF in monotherapy. From these patients, 53 (62%) achieved clinical remission, and 16 (19%) had a partial response. Patients who restarted anti-TNF in monotherapy achieved clinical remission less frequently than those who restarted anti-TNF combined with IMMs (68% vs. 78%; P =0.08). Th e frequency of allergic reactions was similar among patients who restarted anti-TNF in monotherapy and those who restarted combo therapy (5.2% vs. 5.8%). 
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sion, whereas the reported risk of relapse in the long term (≥25 months) was ∼ 50% ( 14 ) . Th erefore, it seems that, over time, a relevant proportion of patients who stopped anti-TNF therapy will relapse. However, it is also true that a signifi cant group of patients will maintain remission for a long period aft er stopping treatment. Accordingly, it is essential to identify the factors associated with risk of relapse. We found that older age at discontinuation was a predictive factor of a lower risk of relapse, possibly because younger age has been identifi ed as a predictive factor of poor outcome, as younger patients oft en have a more aggressive disease course ( 28 ) . Th erefore, patients diagnosed with IBD at younger ages oft en begin anti-TNF treatment sooner than those diagnosed at older ages ( 28 ) . Indeed, in a recent study, Papamichael et al. ( 29 ) followed 100 CD patients who discontinued IFX upon achieving clinical remission for a median of 10 years and found a risk of relapse of 48%. Moreover, the authors found that age of ≥25 years at diagnosis of IBD was the only independent predictive factor for sustained clinical remission aft er discontinuation.
In this study, ADA was associated with a higher relapse rate. For many years, IFX has been the only anti-TNF agent approved for IBD, thus explaining why ADA has been used as the second anti-TNF agent in many patients in whom IFX has previously failed or has lost effi cacy. However, in the multivariate analysis, treatment with a previous anti-TNF agent was not associated with a higher risk of relapse aft er discontinuation. Finally, this fi nding could be a proxy for undetected variables that were not evaluated and that could be associated with a higher risk of relapse aft er discontinuation of anti-TNF therapy. Nevertheless, even though the higher risk of relapse aft er discontinuation of ADA was statistically signifi cant, its magnitude was relatively low (HR=1.29; 95% CI=1.03-1.6) and, therefore, of uncertain clinical relevance.
Th e top-down strategy (i.e., early introduction of anti-TNF agents combined with thiopurines) is frequently used in patients with moderate to severe IBD and with predictive factors of poor outcome (e.g., younger age at diagnosis, early need for corticosteroids, fi stulizing phenotype, and perianal disease) ( 30 ) . Patients who discontinue anti-TNF therapy aft er a top-down strategy are usually in stable remission (clinical, endoscopic, radiologic, and biochemical) before stopping therapy. Moreover, the rate of mucosal healing has been reported to be higher aft er a top-down strategy than with the conventional step-up approach; in addition, the top-down strategy could favor sustained remission ( 4 ). Th ese observations might explain why, in our study, patients who electively stopped anti-TNF agents and those who discontinued treatment owing to adverse events presented a signifi cantly higher risk of relapse than those in whom anti-TNF drugs were stopped as part of a top-down strategy. Moreover, patients with a top-down approach were always naive to IMMs. Consequently, IMMs alone might have been enough to maintain disease remission in some of these patients aft er stopping anti-TNF therapy. On the contrary, the patients in whom anti-TNF agents had been prescribed for a previous failure to IMMs probably have a higher risk of relapse aft er stopping anti-TNFs, even when IMMs are maintained. Although our fi ndings seem logical for all the reasons set out above, the small sample size in the top-down group means that our results should be treated with caution.
Almost all the patients who underwent endoscopy before discontinuing anti-TNF drugs had inactive disease, although activity was mild in most of those with active disease. Th ese fi ndings could be explained by the fact that our study refl ects routine clinical practice, in which physicians do not usually consider stopping anti-TNF therapy if moderate or severe endoscopic activity is detected, even though the patient is asymptomatic. A recent systematic review showed that the relapse rate was lower when discontinuation of anti-TNF treatment was based on both clinical and endoscopic remission as opposed to clinical remission alone ( 7 ) . In this respect, a very recent meta-analysis showed that the incidence of relapse in CD patients, in whom the discontinuation of anti-TNF treatment was based exclusively in clinical remission, was 42%. Similar fi ndings were observed in UC patients. However, if the anti-TNF was discontinued in patients in both clinical and endoscopic remission, the relapse rate was 26% ( 14 ) . Th ese fi ndings suggest that mucosal healing is a major factor that should be evaluated when considering withdrawal of anti-TNF therapy. Nevertheless, other studies, including ours, were not able to demonstrate an association between mucosal healing and a lower relapse rate, either in CD and UC patients ( 10, 15, 17, 29, 31 ) .
As for type of IBD, although some studies found a nonsignifi cant trend for longer remission in patients with UC ( 11 ), our results showed no diff erences in the risk of relapse between CD and UC patients, even when we compared luminal and perianal involvement separately for both CD and UC.
Approximately two-thirds of the patients in this cohort maintained IMMs aft er stopping anti-TNF drugs, and this was associated with a lower relapse rate. Not receiving concomitant medication with IMMs aft er stopping anti-TNF treatment has been associated with a higher risk of relapse ( 8, 32 ) . IMMs enhance the effi cacy of anti-TNF therapy, both in the short term and, probably, in the long term; accordingly, concomitant use of anti-TNF drugs with thiopurines, regardless of whether they had previously failed, is generally recommended in clinical practice ( 33 ) . Th is benefi cial eff ect of the IMMs might explain the lower risk of relapse in patients who maintained these drugs aft er stopping anti-TNF drugs. Finally, we did not fi nd diff erences in the risk of relapse between patients who maintained thiopurines and those who maintained methotrexate, although the sample of the methotrexate group was too small to draw defi nitive conclusions.
When we performed a multivariate analysis separately for CD, the factors associated with the risk of relapse were the same as for the overall IBD patients. Moreover, we found that colonic localization (vs. ileal) and stricturing behavior (vs. infl ammatory) were associated with a higher risk of relapse. However, these results should be taken with caution as they are part of a sensitivity analysis.
According to our results, retreatment with the same anti-TNF drug in IBD patients who relapsed aft er discontinuation was quite eff ective, inducing remission in 75% of patients. Even though similar fi ndings have been reported in other studies, none has included relapses, the response to retreatment with the same anti-TNF is usually eff ective and safe.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ The risk of relapse after anti-tumor necrosis factor-α (anti-TNF) withdrawal is not well known.
✓ The variables that affect clinical course after withdrawal are not well known.
✓ The effi cacy and safety of retreatment with the same anti-TNF drug in patients who relapse seem to be high.
✓ Currently available data are insuffi cient to make recommendations on when anti-TNF therapy can be stopped.
WHAT IS NEW HERE
✓ Approximately half of the patients who discontinued anti-TNF agents because of clinical remission relapse after discontinuation.
✓ Treatment with adalimumab (ADA), elective discontinuation of anti-TNF drugs, and discontinuation because of adverse events increase the risk of relapse.
✓ Treatment with immunomodulators (IMMs) and older age at discontinuation are associated with a lower risk of relapse.
✓ Discontinuation of anti-TNF therapy cannot be universally recommended. However, some patients can stop anti-TNF therapy safely and remain in remission for long periods.
as large a sample as this study ( 7, 10, 16, 34, 35 ) . Th e high effi cacy of reinitiation of anti-TNF drugs may merely refl ect the fact that the patients treated with these drugs are a specifi c group who were previously identifi ed as responders to anti-TNF therapy.
Patients who restarted anti-TNF in monotherapy achieved clinical remission less frequently than those who restarted anti-TNF in combination with IMMs (62% vs. 78%; P =0.08). Although this diff erence was not statistically signifi cant, there was a trend to a lower response in patients on anti-TNF in monotherapy. Moreover, in our study, the frequency of allergic reactions was similar among patients who restarted anti-TNF in monotherapy and those who restarted combo therapy. Th ese fi ndings are in agreement with data reported by other authors ( 35 ) .
Finally, we found that retreatment with the same anti-TNF drug was generally safe. However, 34 patients experienced adverse events which led to withdrawal in 11 patients. For this reason, the decision of stopping anti-TNF therapy should be individualized, and potential consequences (risks and benefi ts) should always be discussed with the patient.
Our study has several limitations. First, it is retrospective; therefore, the decision to stop anti-TNF agents was based on the subjective criteria of each physician. Moreover, the endoscopic scoring system was applied to individual patient reports, and the clinical activity scales were calculated reviewing medical records. Second, only half of the patients underwent endoscopic assessment at discontinuation. For this reason, and because most of the endoscopic lesions, if any, were mild, it was not possible to accurately determine whether mucosal healing was a predictor of a lower risk of relapse. However, considering that our study refl ects daily clinical practice, the fact that a signifi cant proportion of patients had undergone endoscopic evaluation was relevant. Furthermore, although laboratory parameters were collected from medical records, biochemical data were obtained only in a small number of patients.
One of the strengths of this study is that-to our knowledgeit was based on the largest cohort of patients in whom anti-TNF therapy has been discontinued. In addition, data were collected from 78 Spanish hospitals, and the follow-up period was long, with a considerable number of patients followed for >5 years.
In conclusion, the results of this large multicenter study showed that approximately half of the patients who discontinued anti-TNF agents because of clinical remission relapse aft er discontinuation. We found that treatment with ADA, elective discontinuation of anti-TNF drugs, and discontinuation because of adverse events (vs. top-down strategy) were associated with a higher risk of relapse aft er discontinuation. On the contrary, the maintenance of treatment with IMMs and older age at discontinuation are associated with a lower risk of relapse. Based on these fi ndings, discontinuation of anti-TNF therapy cannot be universally recommended in routine clinical practice. However, it seems that some patients can stop anti-TNF therapy safely and remain in remission for long periods. Th e decision whether to continue with anti-TNF drugs should be taken on an individual basis and discussed with the patient. If the drug is discontinued and the patient with IBD
